Published in J Clin Oncol on August 19, 2013
Clinical considerations for biosimilar antibodies. EJC Suppl (2013) 0.89
Nature and importance of follicular lymphoma precursors. Haematologica (2014) 0.85
Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. Cancer Manag Res (2015) 0.78
Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? Bone Marrow Transplant (2015) 0.77
One size does not fit all in follicular lymphoma. J Clin Oncol (2013) 0.76
Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. World J Transplant (2015) 0.75
Follicular Lymphoma: The Management of Elderly Patient. Mediterr J Hematol Infect Dis (2017) 0.75
Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL. Nat Rev Clin Oncol (2013) 0.75
Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable? Haematologica (2015) 0.75
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Extracorporeal Co2 removal in hypercapnic patients at risk of noninvasive ventilation failure: a matched cohort study with historical control. Crit Care Med (2015) 5.22
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med (2011) 4.50
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet (2009) 4.25
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol (2013) 3.58
Early vs late tracheotomy for prevention of pneumonia in mechanically ventilated adult ICU patients: a randomized controlled trial. JAMA (2010) 3.20
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol (2004) 2.90
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood (2008) 2.68
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood (2002) 2.57
Maternal complications and procedures in pregnancy and at birth and wheezing phenotypes in children. Am J Respir Crit Care Med (2006) 2.56
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood (2003) 2.56
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood (2009) 2.54
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (2002) 2.38
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica (2002) 2.34
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica (2008) 2.29
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol (2013) 2.28
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14
Elective surgery for giant bullous emphysema: a 5-year clinical and functional follow-up. Chest (2005) 2.10
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol (2006) 2.09
Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov Disord (2012) 1.98
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol (2014) 1.92
Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood (2004) 1.91
Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev (2009) 1.89
Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma (2006) 1.88
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol (2011) 1.84
Risk of non-Hodgkin lymphoma in celiac disease. JAMA (2002) 1.81
Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int (2004) 1.78
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol (2010) 1.77
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood (2011) 1.76
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol (2010) 1.76
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood (2011) 1.76
Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica (2004) 1.72
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol (2008) 1.69
Deep impact of ultrasound in the intensive care unit: the "ICU-sound" protocol. Anesthesiology (2012) 1.68
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol (2008) 1.64
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol (2010) 1.63
Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood (2003) 1.62
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol (2011) 1.61
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma (2011) 1.60
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood (2009) 1.59
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood (2012) 1.59
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood (2011) 1.59
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology (2014) 1.58
Prolonged left ventricular twist in cardiomyopathies: a potential link between systolic and diastolic dysfunction. Eur J Echocardiogr (2011) 1.57
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. Am J Hematol (2008) 1.57
T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation (2005) 1.56
Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus. Ann Intern Med (2005) 1.55
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. Eur J Haematol (2014) 1.55
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol (2009) 1.54
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma (2007) 1.54
Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma (2007) 1.53
Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. J Gen Intern Med (2007) 1.53
Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene (2005) 1.51
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.51
Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma (2009) 1.51
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol (2012) 1.50
Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma (2013) 1.49
Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum (2002) 1.48
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. Leuk Lymphoma (2011) 1.48
Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leuk Lymphoma (2012) 1.48
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience. Leuk Res (2011) 1.47
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group. J Clin Oncol (2008) 1.46
Epicardial coronary artery size in hypertensive and physiologic left ventricular hypertrophy. Am J Hypertens (2007) 1.46
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. Leuk Lymphoma (2015) 1.46
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol (2006) 1.46
Non sustained ventricular tachycardia in hypertrophic cardiomyopathy and new ultrasonic derived parameters. J Am Soc Echocardiogr (2010) 1.45
Incidental vertebral compression fractures in imaging studies: Lessons not learned by radiologists. World J Radiol (2010) 1.44
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias. Br J Haematol (2003) 1.44
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol (2010) 1.42
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood (2012) 1.42
Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS (2003) 1.40